Document:

EXHIBIT 10.7

 

NANO VIBRONIX, INC.

 

FORM OF SUBSCRIPTION AGREEMENT

SERIES B CONVERTIBLE PREFERRED STOCK

AND WARRANTS

 

SUBSCRIPTION AGREEMENT
(the “Agreement”) dated as of March ___, 2009 between Nano Vibronix, Inc., a Delaware corporation (the “Company”),
and the persons who execute this agreement as investors (collectively, the “Investors”).

 

WITNESSETH:

 

WHEREAS, the Company
desires to sell to the Investors, and the Investors desire to purchase, an aggregate of _______ shares of Series B Convertible
Preferred Stock, par value $.001 per share, of the Company (the “Shares”) with warrants, in substantially the
form attached hereto as Exhibit 1, exercisable to purchase an aggregate of ____ Shares at $17.25 per share, subject to adjustment
(the “Warrants”), all for an aggregate price of US$______.

 

NOW, THEREFORE, in
consideration of the mutual covenants contained herein, the parties hereto hereby agree as follows:

 

1.           Purchase
and Sale of Securities.

 

1.1.       Sale
and Issuance of Securities. The Company shall sell to the Investors and the Investors shall purchase from the Company, an aggregate
of (x) _____ Shares (the “Purchased Shares”) and (y) Warrants to purchase an aggregate of _____ shares of Common
Stock (the “Purchased Warrants” and, collectively with the Purchased Shares, the “Securities”),
for an aggregate purchase price of US$______.

 

1.2.       The
closing (the “Closing”) of the purchase and sale of the Securities hereunder shall take place within three
(3) business days of the date of this Agreement or such other date agreed to by the Company and the Investors (the “Closing
Date”). The Closing shall take place remotely by means of and concurrently with the electronic or facsimile exchange
of documents and signatures at the Company or at such location as is mutually acceptable to the Investors and the Company. At the
Closing:

 

(a)          each
Investor shall deliver to the Company by wire transfer as set forth below:

 

	Mellon Bank Pittsburdgh, PA	 
	ABA # :  	043000261
	FFC:	Merrill Lynch
	Account # : 	101-1730
	Name on the account:	NanoVibronix Inc
	FFC:	831-07B23

 

or such other
method of payment as the Company shall approve, an amount equal to the purchase price of the Securities purchased by such Investor
hereunder; and

 

    	 

    	 

    

  

(b)          the
Company shall issue and deliver to each Investor a stock certificate registered in the name of the Investor, representing the number
of Purchased Shares purchased by such Investor, and the number of Purchased Warrants purchased by such Investor; and

 

(c)          the
Company shall have obtained all requisite approvals and waivers of its Board of Directors and stockholders with respect to the
transactions described herein and the amendment and restatement of the Company’s certificate of incorporation in substantially
the form attached hereto as Exhibit 2 and shall have filed such certificate with the Secretary of State of the State of
Delaware.

 

2.           Representations
and Warranties of the Company. The Company hereby makes the following representations and warranties only:

 

2.1           The
Company (i) is a corporation duly organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation,
(ii) has the corporate power and authority to own or lease its properties as and in the places where such business is conducted
and to carry on its business as conducted, and (iii) is duly qualified as a foreign corporation authorized to do business in every
jurisdiction where the failure to so qualify, individually or in the aggregate, would have a material adverse effect on the operations,
assets, liabilities, financial condition or business of the Company or its subsidiary (“Material Adverse Effect”).

 

2.2           The
subsidiary is duly incorporated and validly existing under the laws of its jurisdiction of incorporation and is qualified to do
business as a foreign corporation in each jurisdiction in which qualification is required, except where failure to so qualify would
not have a Material Adverse Effect.

 

2.3           As
of the date of this Agreement (assuming that the Restated Certificate has been filed) and as of the Closing, the Company (i) has
the requisite corporate power and authority to execute, deliver and perform this Agreement and the other documents set forth in
Section 1.2 above (“Transaction Documents”) and to incur the obligations herein and therein and (ii) has been authorized
by all necessary corporate action to execute, deliver and perform this Agreement and the other Transaction Documents and to consummate
the transactions contemplated hereby and thereby (the “Contemplated Transactions”).

 

2.4           Each
of this Agreement and the other Transaction Documents is a valid and binding obligation of the Company enforceable in accordance
with its terms except as limited by applicable bankruptcy, reorganization, insolvency, moratorium or similar laws affecting the
enforcement of creditors’ rights and the availability of equitable remedies (regardless of whether such enforceability is
considered in a proceeding at law or equity).

 

2.5           
As of the date of this Agreement (assuming that the Restated Certificate has been filed) and as of the Closing, the issuance of
the Securities has been duly authorized by all necessary corporate action on the part of the Company and, when issued to, delivered
to, and paid for by the Investors in accordance with this Agreement, the Purchased Shares will be validly issued, fully paid and
non-assessable.

 

    	2

    	 

    

 

3.           Representations
and Warranties and Agreement of the Investors. Each Investor represents and warrants to the Company as follows:

 

3.1.        Authorization.
Each Investor (i) has full power and authority to execute, deliver and perform this Agreement and the other Transaction Documents
to which it is a party and to incur the obligations herein and therein and (ii) if applicable, has been authorized by all necessary
corporate action to execute, deliver and perform this Agreement and the other Transaction Documents and to consummate the Contemplated
Transactions. Each of this Agreement and the other Transaction Documents is a valid and binding obligation of Investor enforceable
in accordance with its terms, except as limited by applicable bankruptcy, reorganization, insolvency, moratorium or similar laws
affecting the enforcement of creditors’ rights and the availability of equitable remedies (regardless of whether such enforceability
is considered in a proceeding at law or equity).

 

3.2.        Securities
Laws Representations and Covenants of Investors.

 

(a)          This
Agreement is made with each Investor in reliance upon such Investor’s representation to the Company, which by such Investor’s
execution of this Agreement such Investor hereby confirms, that the Securities to be received by such Investor will be acquired
for investment for such Investor’s own account, not as a nominee or agent, and not with a view to the resale or distribution
of any part thereof such that such Investor would constitute an “underwriter” under the Securities
Act of 1933, as amended (the “Securities Act”). The Investor has not granted any right to any other person to
acquire the Securities purchased by such Investor or the shares of the Company issuable upon the conversion or exercise of the
Securities (“Underlying Shares”) except as permitted by the Securities Act and other applicable securities laws.

 

(b)          Each
Investor understands and acknowledges that the offering of the Securities pursuant to this Agreement will not be registered under
the Securities Act or qualified under any other applicable securities laws on the grounds that the offering and sale of the Securities
are exempt from registration and qualification and that the Company’s reliance upon such exemption is predicated upon such
Investor’s representations set forth in this Agreement.

 

(c)          Each
Investor covenants that, unless the Purchased Shares, the Purchased Warrants, the Underlying Shares or any other shares of capital
stock of the Company received in respect of the foregoing have been registered pursuant to the Securities Act, such Investor will
not dispose of such securities unless and until such Investor shall have notified the Company of the proposed disposition and shall
have furnished the Company with an opinion of counsel reasonably satisfactory in form and substance to the Company and its counsel
to the effect that (i) such disposition will not require registration under the Securities Act and (ii) appropriate action
necessary for compliance with the Securities Act and any applicable state, local or foreign law has been taken. Therefore, such
Investor may be required to hold such securities for an indeterminate period.

 

    	3

    	 

    

 

(d)         Each
Investor further represents that such Investor (i) is able to fend for itself in the Contemplated Transactions; (ii) has such
knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of such Investor’s
prospective investment in the Securities; (iii)  has the ability to bear the economic risks of such Investor’s prospective
investment and can afford the complete loss of such investment; (iv)  has received all the information it considers necessary
or appropriate for deciding whether to purchase the Securities; (v)  has had access to officers of the Company and an opportunity
to ask questions of and receive satisfactory answers from such officers; (vi) qualifies as an “accredited investor”
as such term is defined under Rule 501 promulgated under the Securities Act; and (vi) in the case a corporation, a partnership,
a trust or other business entity, further represents by execution of this Agreement that it has not been organized for the purpose
of purchasing the Securities.

 

(e)         The
maximum liability of the Company under this Agreement to each Investor shall not exceed the purchase price paid by such Investor.
An Investor may not bring any claim arising out of this Agreement unless written notice of the claim shall have been given to the
Company no later than 3 months following of the date that the Company's financial statements for the period ending 31 December
2009 shall be made available.

 

(f)          Each Investor
shall provide all information and execute all documents that the Company shall deem necessary to prepare and file with the SEC
a Form D concerning the sale of the Securities.

 

3.3.         Legends.
All certificates for the Securities, and the Underlying Shares, and each certificate representing any shares of capital stock of
the Company received in respect of the foregoing, and each certificate for any such securities issued to subsequent transferees
of any such certificate shall bear the following legend:

 

			“THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT
BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF REGISTRATION OR
AN EXEMPTION THEREFROM UNDER SAID ACT.”

 

In addition, such certificates shall bear
any legend that, in the opinion of the Company’s counsel, is required under the other Transaction Documents or pursuant to
any state, local or foreign law governing the Securities or the Underlying Shares.

 

3.4.       Brokers or Finders. Each Investor
represents and warrants that neither the Company nor the Investor has incurred, directly or indirectly, as a result of any action
taken by the Investor, any liability for brokerage of finders’ fees or agents’ commissions or any similar charges in
connection with this Agreement.

 

    	4

    	 

    

 

3.5.      Buyout
Proposal.  If at any time (i) the Company receives from any third party (in which no stockholder has a significant
interest) a bona fide offer or proposal (a “Buyout Proposal”) to purchase all of the shares of the Company, or all
or substantially all of the assets of the Company, or to effect a merger or consolidation with the Company, which is conditioned
upon the sale of all shares of the Company to such third party or stockholder approval and (ii) the holders of shares representing
seventy five percent (75%) of the aggregate voting power of the Company approve the Buyout Proposal, then the Investors shall transfer
their stock in the Company to such third party or shall vote in favor of the proposed Buyout Proposal, as applicable.

 

4. Adjustments.

 

4.1  Definitions.

 

(a)      “Issuance
Conversion Event” shall mean an aggregate investment in the Company of $1,000,000 or more in which the Company shall have
issued shares in the Company or securities (including convertible debt) exercisable or convertible into shares in the Company at
a specific price per share, other than shares issued (i) to employees, directors or consultants pursuant to any equity compensation
plan or otherwise approved by the Company’s Board of Directors; (ii) by reason of a stock dividend, stock split, split-up
or other distribution of shares of Common Stock; (iii) to bona fide leasing companies, strategic partners, or major lenders; or
(iv) upon conversion or exercise of options, warrants or other convertible securities which are outstanding at the date of this
Agreement.

 

(b)      “Non-Qualifying
Issuance” shall mean an aggregate investment in the Company of less than $1,000,000 which is otherwise described in Section
4.1(a) above.

 

(c)      “Entity
Conversion Event” shall mean a reorganization, consolidation or merger of the Company into or with any other entity (other
than a transaction as a result of which the stockholders of the Company immediately prior to such transaction hold a majority of
the combined voting power of the surviving entity immediately after such transaction), the sale of all or substantially all of
the Company’s business assets, or the sale of all or substantially all of the shares in the Company.

 

(d)      “Conversion
Period” shall mean the period commencing immediately after the completion of the current round of investment and ending on
March 31, 2012.

 

4.2  The Securities
shall be subject to exchange and/or modification (as described below) upon the first to occur of the following events or election
during the Conversion Period:

 

(a)  In the event that
an Issuance Conversion Event shall occur during the Conversion Period, the Securities purchased under this Agreement and any Underlying
Shares purchased pursuant to the Warrants shall automatically be cancelled and shall represent solely the right to receive such
number of Issuance Conversion Event securities which would have been issued to such Investor pursuant to the terms of such Issuance
in consideration for the sum of: (1) the purchase price paid by the Investor hereunder, (2) any purchase price previously paid
in connection with any prior exercise of the Warrants, plus (3) simple interest at 8% per annum from the date of payment of such
amounts provided that   the purchase price for such Issuance Conversion Event securities shall be deemed reduced by
thirty (30%) percent.

 

    	5

    	 

    

 

(b) The Company shall
give the Investor written notice of each Non-Qualifying Issuance. Within 10 days of the Company’s notice, the Investor may
elect by written notice to the Company and the surrender of his Securities and any Underlying Shares purchased pursuant to the
Warrants to receive in exchange therefor such number of Non-Qualifying Issuance securities which would have been issued to him
in consideration for the sum of: (1) the purchase price paid by the Investor hereunder, plus (2) any purchase price previously
paid in connection with any prior exercise of the Warrants.

 

(c)  In the event that
an Entity Conversion Event shall occur during the Conversion Period, the Investor may elect to receive, in lieu of any distribution
due under the Amended and Restated Certificate of Incorporation and in cancellation of his Purchased Shares, proceeds (to the extent
available before any distributions are made to the holders of Series A Stock or Common Stock) equal to: (i) 130% of the purchase
price paid under this Agreement, plus (ii) an amount equal to simple interest on the purchase price at 8% per annum from the date
of payment.

 

4.3  In the event that
during the Conversion Period, a Conversion Event shall not have occurred and the Investor shall not have elected to exchange such
Investor’s Securities as set forth in Section 4.2(b) above, (a) the Investor shall be issued additional shares of Series
B Convertible Preferred Stock such that the Investor’s average purchase price for the Purchased Shares and the additional
shares issuable under this Section shall be $10.00 per share; and (b) the Purchased Warrants shall be amended so that the “Purchase
Price” therein shall be $10.00 per share and the aggregate number of Warrants increased accordingly. (Such $10.00 amount
shall be appropriately adjusted in the case of stock dividend, stock split or combination.)

 

5.           Miscellaneous.

 

5.1.       Entire
Agreement; Successors and Assigns. This Agreement (including all schedules and exhibits thereto) constitutes the entire contract
between the parties relative to the subject matter hereof and thereof. Any previous agreement among the parties with respect to
the sale of the Securities is superseded by this Agreement. The terms and conditions of this Agreement shall inure to the benefit
of and be binding upon the respective executors, administrators, heirs, successors and assigns of the parties. Except as expressly
provided herein, nothing in this Agreement, expressed or implied, is intended to confer upon any party, other than the parties
hereto, any rights, remedies, obligations or liabilities under or by reason of this Agreement.

 

5.2.       Governing
Law; Jurisdiction. This Agreement shall be governed by and construed in accordance with the General Corporation Law of the
State of Delaware as to matters within the scope thereof, and as to all other matters shall be governed by and construed in accordance
with the internal laws of the State of New York without regard to principles of conflicts of law. Each party hereby irrevocably
consents and submits to the jurisdiction of any New York State or United States Federal Court sitting in the State of New York,
County of New York, over any action or proceeding arising out of or relating to this Agreement and irrevocably consents to the
service of any and all process in any such action or proceeding by registered mail addressed to such party at its address shown
below. Each party further waives any objection to venue in New York and any objection to an action or proceeding in such state
and county on the basis of forum non-conveniens. Each party also waives any right to trial by jury.

 

    	6

    	 

    

 

5.3.       Counterparts.
This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument.

 

5.4.       Headings.
The headings of the sections of this Agreement are for convenience and shall not by themselves determine the interpretation of
this Agreement.

 

5.5.      Notices. Any notice required or permitted
hereunder shall be given in writing and shall be deemed effectively given upon personal delivery and if a fax number has been provided,
upon delivery (with answerback confirmed), addressed to a party at its address and the fax number, if any, shown below or at such
other address and fax number as such party may designate by three days advance notice to the other party.

 

Any notice to the Investors shall be sent to the addresses set forth on the signature pages hereof.

 

	Any notice to the Company shall be sent to:	With a copy to:
	Nano Vibronix Inc.	 	 
	601 Chestnut Street	 	 
	Cedarhurst, NY 11516	 	Nano Vibronix, Inc.
	Attention: Dr. Harold Jacob	 	Fax:   +972 4 820 2794
	Fax: 516 569 6872	 	 

 

5.6.        Severability.
Whenever possible, each provision of this Agreement shall be interpreted in such a manner as to be effective and valid under applicable
law, but if any provision of this Agreement shall be deemed prohibited or invalid under such applicable law, such provision shall
be ineffective to the extent of such prohibition or invalidity, and such prohibition or invalidity shall not invalidate the remainder
of such provision or any other provision of this Agreement.

 

5.7.       Expenses.
Irrespective of whether the Closing is effected, the Company shall pay all costs and expenses that it incurs with respect to the
negotiation, execution, delivery and performance of this Agreement. Each Investor shall be responsible for all costs incurred by
it in connection with the negotiation, execution, delivery and performance of this Agreement including, but not limited to, legal
fees and expenses.

 

5.8        Amendments
and Waivers. Any provision of this Agreement may be amended and the observance of any provision of this Agreement may be waived
(either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the
Company and the holders of a majority of the aggregate then-outstanding Shares. Any amendment or waiver effected in accordance
with this Section shall be binding upon each holder of any securities purchased under this Agreement at the time outstanding (including
the Underlying Shares or other securities into which such securities are convertible), each future holder of all such securities,
and the Company.

 

[REMAINDER OF PAGE INTENTIONALLY BLANK]

 

    	7

    	 

    

 

SIGNATURE PAGE

TO

NANO VIBRONIX INC.

SUBSCRIPTION AGREEMENT

  

IF the PURCHASER is an INDIVIDUAL, please
complete the following:

 

IN WITNESS WHEREOF, the undersigned has
executed this Agreement this __ day of ______________.

 

Amount of Subscription:

$_________ 

 

	Number of Purchased Shares:	 	Investor Name:
	 	 	 
	 	 	 
	 	 	Signature of Investor
	 	 	 
	 	 	 
	 	 	Social Security Number
	 	 	 
	 	 	 
	 	 	Address and Fax Number
	 	 	 
	 	 	 
	 	 	 
	ACCEPTED AND AGREED:	 	 
	 	 	 
	NANO VIBRONIX INC.	 	 
	 	 	 
	By:	 	 	 	 
	 	Name:	 	 
	 	Title:	 	 

 

	Dated:  	 	 	 

 

    	 

    	 

    

 

SIGNATURE PAGE

TO

NANO VIBRONIX, INC.

SUBSCRIPTION AGREEMENT

 

IF the INTERESTS will be held as JOINT TENANTS,
as TENANTS IN COMMON, or as COMMUNITY PROPERTY, please complete the following:

 

IN WITNESS WHEREOF, the undersigned has
executed this Agreement this __ day of ____________.

 

	Amount of Subscription:	 	 
	$__________________	 	Print Name of a Purchaser
	 	 	 
	Number of Purchased Shares:	 	 
	___________	 	Signature of a Purchaser
	 	 	 
	 	 	 
	 	 	Print Name of Spouse or Other Purchaser
	 	 	 
	 	 	 
	 	 	Signature of Spouse or Other Purchaser
	 	 	 
	 	 	 
	 	 	Social Security Number
	 	 	 
	 	 	 
	 	 	Address
	 	 	 
	 	 	 
	 	 	 
	ACCEPTED AND AGREED:	 	 
	 	 	 
	NANO VIBRONIX INC.	 	 
	 	 	 
	By:	 	 	 
	 	Name:	 	 
	 	Title:	 	 
	 	 	 
	Dated: ________________	 	 

 

    	 

    	 

    

 

SIGNATURE PAGE

TO

NANO VIBRONIX INC.

SUBSCRIPTION AGREEMENT

 

IF the PURCHASER is a PARTNERSHIP, CORPORATION,
TRUST or OTHER ENTITY, please complete the following:

 

IN WITNESS WHEREOF, the undersigned has
executed this Agreement this __ day of ______________.

 

	Amount of Subscription:	 	 
	$___________________	 	 
	 	 	 
	Number of Purchased Shares:	 	 
	_____________	 	 
	 	 	 
	 	 	Print Full Legal Name of Partnership,
	 	 	Company, Trust or Other Entity
	 	 	 
	 	 	By:	 
	 	 	 	     (Authorized Signatory)
	 	 	Name:	 
	 	 	Title:	 

 

	 	 	Address and Fax Number:	 
	 	 	 
	 	 	 

 

	 	Employer Identification Number: _________
	 	Date and State of Incorporation or Organization:______________________
	 	Date on which Taxable Year Ends:_________________________________

 

ACCEPTED AND AGREED:

	 
	NANO VIBRONIX INC.
	 
	By:	 	 
	Name:
	Title:
	
	Dated:

 

    	-2-EXHIBIT 10.8

 

NANO VIBRONIX, INC.

 

FIRST AMENDMENT TO

SUBSCRIPTION AGREEMENT

SERIES B CONVERTIBLE PREFERRED STOCK

AND WARRANTS

 

FIRST AMENDMENT TO SUBSCRIPTION
AGREEMENT SERIES B CONVERTIBLE PREFERRED STOCK AND WARRANTS (this “Amendment”) dated as of November 14,
2011 between Nano Vibronix, Inc., a Delaware corporation (the “Company”), and the persons who execute this
agreement as investors (collectively, the “Investors”).

 

WITNESSETH:

 

WHEREAS, the
Company entered into a Subscription Agreement Series B Convertible Preferred Stock and Warrants, dated as of March 20, 2009
with the persons who executed such agreement as investors (the “Subscription Agreement”);

 

WHEREAS, pursuant to
Section 5.8 of the Subscription Agreement, any provision of the Subscription Agreement may be amended with the written consent
of the Company and the holders of a majority of the aggregate then-outstanding shares of Series B Convertible Preferred Stock of
the Company;

 

WHEREAS, the Company
and the holders of a majority of the aggregate outstanding shares of Series B Convertible Preferred Stock desire to amend Section
4.2(a) of the Subscription Agreement as set forth below.

 

NOW, THEREFORE, in consideration
of the mutual covenants contained herein, the parties hereto hereby agree as follows:

 

1. Section 4.2(a) of the Subscription Agreement
is hereby deleted and replaced by the following:

 

(a) In the event that an Issuance
Conversion Event shall occur during the Conversion Period, the Securities purchased under this Agreement (including Warrants which
shall have been exercised as of such date and any Underlying Shares purchased pursuant to such Warrants) shall automatically be
cancelled and shall represent solely the right to receive:

 

(i)  such
number of Issuance Conversion Event securities which would have been issued to such Investor pursuant to the terms of such Issuance
in consideration for the sum of: (1) the purchase price paid by the Investor hereunder, (2) any purchase price previously paid
in connection with any prior exercise of the Warrants, plus (3) simple interest at 8% per annum from the date of payment of such
amounts provided that   the purchase price for such Issuance Conversion Event securities shall be deemed reduced by
thirty (30%) percent provided further that   in the case of an Issuance Conversion Event in which notes convertible
into shares in the Company are issued, (A) the conversion price set forth in such notes shall be reduced by thirty (30%) percent,
and (B) the purchase price for such notes shall not be deemed reduced by thirty (30%) percent; and

 

    	 

    	 

    

 

(ii) warrants
in the form attached hereto as Exhibit A, to purchase such number of securities as shall equal thirty (30%) percent of the number
of Issuance Conversion Event securities issued to the Investor pursuant to Section 4.2(a)(i) hereof, at an exercise price equal
to seventy (70%) percent of the purchase price to investors in the Issuance Conversion Event provided that   in the
case of an Issuance Conversion Event in which notes convertible into shares are issued, (A) the warrants shall grant the right
to purchase such number of shares as shall equal thirty (30%) percent of the number of shares issuable upon conversion of the note
issued to the Investor pursuant to Section 4.2(a)(i) hereof and (B) the exercise price under such warrants shall be equal to the
conversion price in the note issued to the Investor pursuant to Section 4.2(a)(i) hereof.

The liquidation preference (if
any) of any preferred shares issued in such Issuance Conversion Event or upon conversion or exercise of such warrants or convertible
notes shall reflect such reduced purchase price.

 

2. The parties acknowledge that the full
execution by the investors listed on the signature page hereof shall constitute the consent of a majority of the aggregate outstanding
shares of Series B Participating Convertible Preferred Stock of the Company.

 

3. The Subscription Agreement otherwise
remains in full force and effect.

 

IN WITNESS WHEREOF, the undersigned have executed this Amendment
as of the 14 day of November, 2011.

 

Nano Vibronix, Inc.

 

	By:	Harold Jacob	 

 

Investors:

	/s/ JB	 
	INTERNATIONAL
    B MANAGEMENT COMPANY LTD.	 
	AMERICAN
    INVESTMENTS LIMITED	 
	(SIGNED
    BY IBMC, DIRECTOR)	 
	/s/
    Joseph Bronner	 
	/s/
    Jonathan Kahan	 
	/s/
    Alexandria Kelly	 
	/s/
    Miriam Winder Kelly	 
	/s/
    Harold Jacob for MIDI	 
	/s/
    Ira Greenstein	 
	/s/
    Stephen Zuller	 
	/s/ Paul Packer

                                                                                Globis Capital Partners
	 
	/s/ Paul Packer	 
	/s/ Paul Packer

                                                                                Globis Overseas Fund
	 
	/s/
    David Kreinberg

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00227-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00227-of-00352.parquet"}]]